StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) stock

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.15+0.67 (+19.25%)

Close on Nov 17, 2026Market cap $6.07MP/E –Yield –

Earnings

CNS Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of CNS Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2024ended Mar 31, 2024May 16, 2024during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 15, 2023before the open–––Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023before the open–––Release
Q1 FY2023ended Mar 31, 2023May 15, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Aug 15, 2022before the open–––Release
Q1 FY2022ended Mar 31, 2022May 16, 2022after the close–––Release
Q4 FY2021ended Dec 31, 2021Mar 3, 2022before the open–––Release
Q2 FY2021ended Jun 30, 2021Aug 13, 2021before the open–––Filing
Q4 FY2019ended Dec 31, 2019Mar 12, 2020after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

CNS Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When CNS Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases CNS Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. News
  4. Update
  5. Update
  6. News
  7. Update
  8. Update
  9. News
  10. Update
  11. News
  12. News
  13. News
  14. News
  15. Results

See a number that looks wrong?